NASDAQ:SAGESAGE Therapeutics Stock Price, Forecast & News

SAGE Therapeutics' stock was trading at $42.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SAGE stock has increased by 19.9% and is now trading at $50.70.
View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 7 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for SAGE Therapeutics.

SAGE Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for SAGE Therapeutics.

SAGE Therapeutics will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

SAGE Therapeutics Inc (NASDAQ:SAGE) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($2.44) EPS for the quarter, beating the consensus estimate of ($3.17) by $0.73. The biopharmaceutical company earned $2.29 million during the quarter, compared to analysts' expectations of $2.81 million. SAGE Therapeutics had a negative net margin of 7,406.75% and a negative return on equity of 63.13%. The business's revenue was up 391.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($3.37) earnings per share.
View SAGE Therapeutics' earnings history.

17 brokerages have issued 12-month price targets for SAGE Therapeutics' shares. Their forecasts range from $28.00 to $263.00. On average, they expect SAGE Therapeutics' share price to reach $82.11 in the next twelve months. This suggests a possible upside of 62.0% from the stock's current price.
View analysts' price targets for SAGE Therapeutics.

Media headlines about SAGE stock have trended extremely negative on Sunday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. SAGE Therapeutics earned a coverage optimism score of -4.8 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about SAGE Therapeutics.

Some companies that are related to SAGE Therapeutics include Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Emergent Biosolutions (EBS), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), Myokardia (MYOK), Reata Pharmaceuticals (RETA) and Ultragenyx Pharmaceutical (RARE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), salesforce.com (CRM) and Johnson & Johnson (JNJ).

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

SAGE Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (1.89%), Jennison Associates LLC (0.42%), Asymmetry Capital Management L.P. (0.38%), New York State Common Retirement Fund (0.23%), Swiss National Bank (0.22%) and Russell Investments Group Ltd. (0.18%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul.
View institutional ownership trends for SAGE Therapeutics.

SAGE stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Victory Capital Management Inc., New York State Common Retirement Fund, Nisa Investment Advisors LLC, and Arizona State Retirement System.
View insider buying and selling activity for SAGE Therapeutics.

SAGE stock was purchased by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., Russell Investments Group Ltd., WINTON GROUP Ltd, UBS Group AG, Rafferty Asset Management LLC, Swiss National Bank, Mutual of America Capital Management LLC, and Quantitative Systematic Strategies LLC. Company insiders that have bought SAGE Therapeutics stock in the last two years include Albert Robichaud, and Jeffrey M Jonas.
View insider buying and selling activity for SAGE Therapeutics.

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SAGE stock can currently be purchased for approximately $50.70.

SAGE Therapeutics has a market capitalization of $2.63 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-680,240,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.

The official website for SAGE Therapeutics is www.sagerx.com.

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]